SLC19A1 and urinary bladder carcinoma: Prospective evaluation of a panel of folate transporters (like; RFC, BCRP, and MRP3), can predict response to antifolate therapy, suggest new therapeutic strategies and hence, improve the treatment outcome for individual bladder cancer patients.